Lineage Cell Therapeutics Inc. (AMEX: LCTX) At $1.44 Is Worth A Gamble – Marketing Sentinel
Home  »  Technologies   »  Lineage Cell Therapeutics Inc. (AMEX: LCTX) At $1....

Lineage Cell Therapeutics Inc. (AMEX: LCTX) At $1.44 Is Worth A Gamble

During the last session, Lineage Cell Therapeutics Inc. (AMEX:LCTX)’s traded shares were 1.21 million, with the beta value of the company hitting 1.62. At the end of the trading day, the stock’s price was $1.44, reflecting an intraday gain of 2.13% or $0.03. The 52-week high for the LCTX share is $3.00, that puts it down -108.33 from that peak though still a striking 23.61% gain since the share price plummeted to a 52-week low of $1.10. The company’s market capitalization is $247.98M, and the average intraday trading volume over the past 10 days was 0.9 million shares, and the average trade volume was 732.65K shares over the past three months.

Lineage Cell Therapeutics Inc. (LCTX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.20. LCTX has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.06.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Lineage Cell Therapeutics Inc. (AMEX:LCTX) trade information

Lineage Cell Therapeutics Inc. (LCTX) registered a 2.13% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.13% in intraday trading to $1.44 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 15.20%, and it has moved by 15.20% in 30 days. Based on these gigs, the overall price performance for the year is -47.45%. The short interest in Lineage Cell Therapeutics Inc. (AMEX:LCTX) is 10.07 million shares and it means that shorts have 14.45 day(s) to cover.

The consensus price target of analysts on Wall Street is $6.00, which implies an increase of 76.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $8.00 respectively. As a result, LCTX is trading at a discount of -455.56% off the target high and -177.78% off the low.

Lineage Cell Therapeutics Inc. (LCTX) estimates and forecasts

Statistics show that Lineage Cell Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Lineage Cell Therapeutics Inc. (LCTX) shares have gone down -43.97% during the last six months, with a year-to-date growth rate less than the industry average at -21.43% against 0.60. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -100.00% this quarter and then drop -20.00% in the quarter after that. In the rating firms’ projections, revenue will increase 445.30% compared to the previous financial year.

Revenue for the current quarter is expected to be $1.53 million as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $1.54 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $512k and $510k respectively. In this case, analysts expect current quarter sales to grow by 198.80% and then jump by 202.00% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -22.60%. While earnings are projected to return -90.00% in 2022.

LCTX Dividends

Lineage Cell Therapeutics Inc. is due to release its next quarterly earnings between March 09 and March 14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Lineage Cell Therapeutics Inc. (AMEX:LCTX)’s Major holders

Lineage Cell Therapeutics Inc. insiders own 4.67% of total outstanding shares while institutional holders control 44.28%, with the float percentage being 46.45%. Broadwood Capital, Inc. is the largest shareholder of the company, while 149 institutions own stock in it. As of Dec 30, 2021, the company held over 34.01 million shares (or 20.04% of all shares), a total value of $83.31 million in shares.

The next largest institutional holding, with 9.81 million shares, is of Blackrock Inc.’s that is approximately 5.78% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $15.11 million.

Also, the Mutual Funds coming in first place with the largest holdings of Lineage Cell Therapeutics Inc. (LCTX) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 3.44 million shares. This amounts to just over 2.03 percent of the company’s overall shares, with a $8.42 million market value. The same data shows that the other fund manager holds slightly less at 2.88 million, or about 1.70% of the stock, which is worth about $4.55 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]